Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 649,158 | 437,446 | 493,982 | 598,028 | 408,330 |
| Marketable Securities | 416,228 | 316,361 | 590,326 | 797,940 | 381,347 |
| Receivables | 448,351 | 377,404 | 342,633 | 261,365 | 215,280 |
| Inventories | 698,548 | 680,275 | 530,871 | 475,775 | 355,126 |
| Other current assets | 129,934 | 130,657 | 98,403 | 74,036 | 61,708 |
| TOTAL | $2,342,219 | $1,942,143 | $2,056,215 | $2,207,144 | $1,421,791 |
| Non-Current Assets | |||||
| PPE Net | 1,032,471 | 1,010,868 | 948,682 | 896,700 | 798,768 |
| Investments And Advances | 285,473 | 411,978 | 235,864 | 385,785 | 572,711 |
| Intangibles | 613,470 | 653,619 | 688,847 | 714,549 | 750,819 |
| Other Non-Current Assets | 1,574,387 | 671,431 | 497,520 | 428,947 | 479,601 |
| TOTAL | $3,505,801 | $2,747,896 | $2,370,913 | $2,425,981 | $2,601,899 |
| Total Assets | $5,848,020 | $4,690,039 | $4,427,128 | $4,633,125 | $4,023,690 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 361,882 | N/A | 360,949 | 22,478 |
| Accounts payable and accrued liabilities | 492,548 | 570,621 | 523,241 | 455,569 | 416,832 |
| TOTAL | $492,548 | $932,503 | $523,241 | $816,518 | $439,310 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 1,249,470 | 635,155 | 935,947 | 1,007,944 | 818,105 |
| TOTAL | $1,249,470 | $635,155 | $935,947 | $1,007,944 | $818,105 |
| Total Liabilities | $1,742,018 | $1,567,658 | $1,459,188 | $1,824,462 | $1,257,415 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 181,830 | 179,926 | 178,372 | 176,072 | 172,867 |
| Common Shares | 182 | 180 | 178 | 176 | 173 |
| Retained earnings | -861,609 | -1,720,709 | -1,694,134 | -1,637,548 | -1,520,506 |
| Other shareholders' equity | -25,978 | 10,203 | -8,030 | -37,185 | -1,505 |
| TOTAL | $4,106,002 | $3,122,381 | $2,967,940 | $2,808,663 | $2,766,275 |
| Total Liabilities And Equity | $5,848,020 | $4,690,039 | $4,427,128 | $4,633,125 | $4,023,690 |